Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Stock

Equities

2315

CNE100005D27

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E.
Other stock markets
 2024-12-10 		5-day change 1st Jan Change
6.720 CNY +1.66% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +13.90% -43.91%
Nov. 12 Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy MT
Nov. 11 Biocytogen Pharmaceuticals Co., Ltd. Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-In-Class B7H3/PTK7 Topo-Payload Bispecific ADC and Option Exercise CI

Valuation: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Capitalization 2.5B 345M 329M 304M 271M 489M 29.29B 542M 3.79B 1.4B 12.03B 1.3B 1.27B 52.49B P/E ratio 2024 *
-
P/E ratio 2025 * -
Enterprise value 2.55B 352M 335M 310M 276M 498M 29.84B 552M 3.86B 1.43B 12.25B 1.32B 1.29B 53.47B EV / Sales 2024 *
2.69x
EV / Sales 2025 * 1.92x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Dynamic Chart

Latest news: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals Grants Worldwide License for Anti-Tumor Therapy Nov. 12 MT
Biocytogen Pharmaceuticals Co., Ltd. Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-In-Class B7H3/PTK7 Topo-Payload Bispecific ADC and Option Exercise Nov. 11 CI
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 Aug. 28 CI
Biocytogen Pharmaceuticals Expects Narrower Loss in H1 Aug. 07 MT
Biocytogen Pharmaceuticals Co., Ltd. Provides Earnings Guidance for the First Half Period from January 1, 2024 to June 30, 2024 Aug. 07 CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Option and License Agreement with IDEAYA Biosciences for Potential First-In-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program Jul. 31 CI
Biocytogen Pharmaceuticals Enters License Contract with Cancer Drug Firm Jul. 17 MT
SOTIO Biotech Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline Jul. 16 CI
XtalPi Inc. announced that it has received CNY 337 million in funding from Shanghai Guosheng Investment Group, Biocytogen Pharmaceuticals Co., Ltd., FaaS Capital Longevity Limited and other investors Jun. 03 CI
Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies May. 06 CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023 Apr. 26 MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 Mar. 27 CI
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates Mar. 25 CI
More news

Press Releases: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise Nov. 12 AQ
Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform Jun. 24 AQ
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates Mar. 26 AQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development Jan. 24 AQ
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma Jan. 09 AQ
More press releases

Quotes and Performance

1 day+1.66%
1 week+13.90%
Current month+15.07%
1 month+11.81%
3 months+10.89%
6 months-16.31%
Current year-43.91%
More quotes

Course Extremes

1 week
5.80
Extreme 5.8
7.19
1 month
5.60
Extreme 5.6
7.19
Current year
5.60
Extreme 5.6
12.02
1 year
5.60
Extreme 5.6
12.80
3 years
5.60
Extreme 5.6
28.80
5 years
5.60
Extreme 5.6
28.80
10 years
5.60
Extreme 5.6
28.80
More quotes

Managers and Directors: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Director TitleAgeSince
Yue Lei Shen CEO
 Chief Executive Officer - 2009-11-12
Liu Bin DFI
 Director of Finance/CFO - 2020-01-04
Sabrina Wang COO
 Chief Operating Officer - 2019-09-30
Manager TitleAgeSince
Yue Lei Shen CHM
 Chairman - 2013-01-21
Yi Liang Wei BRD
 Director/Board Member 53 2015-11-11
Ke Xiang Zhou BRD
 Director/Board Member 60 2018-03-11
More insiders

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
+1.66%+13.90%-38.91% - 345M
LONZA GROUP AG Stock Lonza Group AG
+0.85%-0.34%+58.93%-30.48%42.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.57%+1.31%-5.61%-24.83%36.88B
CELLTRION, INC. Stock Celltrion, Inc.
+4.00%-2.57%+8.59%-7.13%26.23B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
-1.49%+1.39%-20.74%-22.06%17.83B
MODERNA, INC. Stock Moderna, Inc.
-9.07%-2.51%-48.32%-83.85%15.97B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
-1.30%-1.78%+49.90%+92.10%16.17B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.36%+2.76%+12.90%-33.81%12.25B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-2.92%+0.79%+20.75%+67.08%10.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.33%-1.13%-3.62%-44.92%10.08B
Average -1.25%+1.76%+3.39%-9.77% 18.92B
Weighted average by Cap. -0.88%+0.14%+13.41%-14.87%
See all sector performances

Financials

2024 *2025 *
Net sales 947M 131M 124M 115M 102M 185M 11.08B 205M 1.43B 529M 4.55B 490M 480M 19.86B 1.22B 168M 160M 148M 132M 237M 14.23B 263M 1.84B 680M 5.84B 630M 616M 25.5B
Net income - -
Net Debt 46.62M 6.43M 6.12M 5.67M 5.04M 9.1M 545M 10.09M 70.6M 26.06M 224M 24.13M 23.61M 977M -167M -23M -21.89M -20.29M -18.05M -32.58M -1.95B -36.1M -253M -93.27M -802M -86.36M -84.5M -3.5B
More financial data * Estimated data

Company Profile

Logo Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-editing Services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
Employees
1,040
Sector
Biotechnology & Medical Research
Calendar
2025-03-31 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
24-12-10 6.720 ¥ +1.66% 164,500
24-12-09 6.610 ¥ +8.18% 140,000
24-12-06 6.110 ¥ +0.16% 172,000
24-12-05 6.100 ¥ +5.54% 247,000
24-12-04 5.780 ¥ -2.03% 157,880

End-of-day quote Hong Kong S.E., December 09, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart BIOCYTOGEN-PHARMACEUTICAL More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart BIOCYTOGEN-PHARMACEUTICALMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
6.269CNY
Average target price
12.26CNY
Spread / Average Target
+95.64%
Consensus

Quarterly revenue - Rate of surprise

quality-estimates-chart BIOCYTOGEN-PHARMACEUTICAL Company calendar
  1. Stock Market
  2. Equities
  3. 2315 Stock